Skip to main content

Table 1 Patients’ characteristics and oncological data

From: ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study

VariablesALPPS vs. TSH/PVE analysis
ALPPS (n = 21)TSH/PVE (n = 37)p value
Demographics
 Sex, m/f (%)8 (38)/13 (62)25 (68)/12 (32).029
 Age (years)60 (52–71)60 (52–67).686
 BMI (kg/m2)24 (20–30)25 (23–29).340
 ASA, n (%)  .460
  I2 (10)1 (3) 
  II5 (24)12 (42) 
  III14 (67)24 (65) 
 Rescue ALPPS after failed TSH, n (%)6 (29)n.a.n.a.
Oncologic characteristics
 Timing: synchronous/metachronous9 (43)/12 (57)24 (65)/13 (35).104
 Site of primary  .145
  Right-sided colon6 (29)4 (11) 
  Left-sided colon10 (48)17 (46) 
  Rectum5 (24)16 (43) 
 T category primary  .581
  I/II3 (14)3 (9) 
  III/IV18 (86)29 (91) 
 N category primary  .001
  N09 (43)2 (6) 
  N112 (57)30 (94) 
 Preoperative chemotherapy (y/n)20 (95)/1 (5)21 (57)/16 (43) 
 Number of chemotherapy lines, n (%)  .038
  First-line treatment20 (95)27 (73) 
  Second-line treatment3 (14)7 (19) 
 Number of cycles of chemotherapy8 (6–13)6 (0–13).243
 Chemotherapeutic substance in first line, n (%)  .312
  Oxaliplatin13 (62)14 (38) 
  Irinotecan4 (19)2 (5) 
  Oxaliplatin and Irinotecan2 (10)6 (16) 
  Other/unknown2 (10)5 (14) 
 Chemotherapeutic substance in second line, n (%)  .788
  Oxaliplatin01 (14) 
  Irinotecan1 (33)3 (43) 
  Oxaliplatin and Irinotecan2 (67)2 (29) 
  Other01 (14) 
 Antibody utilization, n (%)14 (67)17 (46).128
 Antibody, n (%)  .476
  Bevacizumab7 (50)12 (71) 
  Cetuximab5 (36)4 (24) 
  Panitumumab2 (14)1 (6) 
 Response to chemotherapy, n (%)#  .794
  Stable disease9 (45)13 (38.2) 
  Partial remission10 (50)20 (58.8) 
  Progressive disease1 (5)1 (2.9) 
 Number of lesions at hepatectomy*3 (1–9)3 (1–8).686
 Largest tumor diameter at hepatectomy (mm)*42 (10–130)33 (4–107).237
Liver function and clinical chemistry
 Albumin (g/l)41 (34–44)41 (39–46).279
 AST (U/l)32 (27–57)31 (24–41).189
 ALT (U/l)32 (22–47)27 (20–38).197
 GGT (U/l)109 (47–316)67 (34–173).080
 Total bilirubin (mg/dl)0.4 (0.2–0.6)0.4 (0.3–0.6).336
 Platelet count (/nl)254 (196–295)257 (199–295).986
 Alkaline Phosphatase (U/l)148 (91–189)92 (76–131).029
 Prothrombin time (%)100 (84–104)100 (93–111).200
 Hemoglobin (g/dl)11.9 (9.9–13.1)13.2 (12.4–14.5).003
  1. ALPPS associating liver partition and portal vein ligation for staged hepatectomy, ALT alanine aminotransferase, AP alkaline phosphatase, ASA American Society of Anesthesiologists classification, AST aspartate aminotransferase, BMI body mass index, CRP c-reactive protein, GGT gamma glutamyltransferase, INR international normalized ratio
  2. #For TSH/PVE patients who did not undergo preoperative chemotherapy, inter-stage chemotherapy was evaluated to determine response to systemic therapy. Data presented as median and interquartile range if not noted otherwise
  3. *Median and range. Categorical data were compared using the chi-squared test, fisher’s exact test or linear-by-linear association according to scale and number of cases. Data derived from continuous variables of different groups were compared by Mann-Whitney U Test